Trissel L A, Martinez J F
Division of Pharmacy, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Am J Hosp Pharm. 1994 Aug 1;51(15):1907-13.
The compatibility of filgrastim with selected drugs during simulated Y-site injection was studied. Five-milliliter samples of filgrastim 30 micrograms/mL in 5% dextrose injection were combined with 5-mL samples of solutions of each of 97 other drugs in 5% dextrose injection at clinically used concentrations at 22 degrees C. Immediately after and one and four hours after the samples were combined, visual examinations were performed in fluorescent light with the unaided eye and with a high-intensity monodirectional light (Tyndall beam) to enhance the visualization of small particles and low-level turbidity. The turbidity of each drug combination was measured as well. Combinations yielding inconclusive results were subjected to particle sizing and counting. Most of the drugs tested were compatible with filgrastim 30 micrograms/mL during the observation period. However, 22 drugs showed various incompatibilities with filgrastim, including filament formation, particulate formation and precipitation, and color change. Filgrastim 30 micrograms/mL in 5% dextrose injection was compatible with 75 drugs for up to four hours at 22 degrees C; 22 drugs were not compatible with filgrastim.
研究了在模拟Y型静脉注射过程中重组人粒细胞刺激因子与选定药物的配伍性。将5毫升浓度为30微克/毫升的重组人粒细胞刺激因子5%葡萄糖注射液样本与5毫升其他97种药物在5%葡萄糖注射液中的临床使用浓度溶液样本在22℃下混合。样本混合后立即以及混合后1小时和4小时，在荧光灯下用肉眼和高强度单向光（丁达尔光束）进行目视检查，以增强对小颗粒和低水平浑浊度的观察。还测量了每种药物组合的浑浊度。对结果不明确的组合进行了颗粒大小测定和计数。在观察期内，大多数受试药物与30微克/毫升的重组人粒细胞刺激因子配伍。然而，22种药物与重组人粒细胞刺激因子表现出各种不相容性，包括丝状形成、颗粒形成和沉淀以及颜色变化。5%葡萄糖注射液中30微克/毫升的重组人粒细胞刺激因子在22℃下与75种药物在长达4小时内配伍；22种药物与重组人粒细胞刺激因子不相容。
